Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Pharmacologic Treatment of Depression During Pregnancy

Article Abstract:

Pregnant women can probably use most antidepressants safely throughout their pregnancy. Researchers analyzed four studies that compared birth outcomes in pregnant women who took antidepressants and those who did not. Exposure to the drugs did not increase the rate of birth defects or fetal death. However, one study found lower birth weights of infants born to mothers who took fluoxetine (Prozac) during pregnancy. The other studies showed no effect on fetal development. Some babies had symptoms of withdrawal symptom shortly after birth.

Author: Gelenberg, Alan J., Frank, Ellen, Wisner, Katherine L., Leonard, Henrietta, Zarin, Deborah
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1999
Complications and side effects, Fetus, Pregnant women, Drug use, Antidepressants

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Efficacy of Venlafaxine Extended-Release Capsules in Nondepressed Outpatients With Generalized Anxiety Disorder: A 6-Month Randomized Controlled Trial

Article Abstract:

Extended-release venlafaxine appears to be effective in the treatment of generalized anxiety disorder (GAD). This was the conclusion of a study of 251 people with GAD who took extended-release venlafaxine or a placebo for up to 28 weeks. About 70% of the patients taking venlafaxine benefited from the drug, compared to 40% of those taking a placebo. Extended-release venlafaxine can be taken once a day. The most common side effects were nausea, sleepiness, and dry mouth.

Author: Gelenberg, Alan J., Lydiard, R. Bruce, Rudolph, Richard L., Aguiar, Loren, Haskins, J. Thomas, Salinas, Eliseo
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2000
Anxiety, Venlafaxine

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Paroxetine Treatment of Generalized Social Phobia (Social Anxiety Disorder)

Article Abstract:

Paroxetine appears to be effective in the treatment of social phobia. Social phobia is a severe form of social anxiety. Researchers randomly assigned 183 patients with social phobia to take paroxetine or a placebo. Fifty-five percent of the people taking paroxetine experienced an improvement, compared to 24% of those taking a placebo. Scores on tests of social anxiety dropped 22% in the group taking paroxetine.

Author: Lydiard, R. Bruce, Stein, Murray B., Liebowitz, Michael R., Gergel, Ivan, Pitts, Cornelius D., Bushnell, William
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1998
Paroxetine, Phobias

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Evaluation, Drug therapy
Similar abstracts:
  • Abstracts: Hormonal treatment for bleeding irregularities in Norplant implant users. Prevalence of enlarged ovarian follicles among users of levonorgestrel subdermal contraceptive implants (Norplant)
  • Abstracts: Assessment of the European classification criteria for Sjogren's syndrome in a series of clinically defined cases: results of a prospective multicentre study
  • Abstracts: Falsely accused and sent to prison for life. One of these men has a secret. He used to be a she. Should you ever divorce your family?
  • Abstracts: This man loves your body. For better, for work. Classic dads, radical daughters
  • Abstracts: A 16-year-old boy with recurrent abdominal pain. A 47-year-old woman with diabetes, Crohn's colitis, and a painful swelling of the foot
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.